Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;10(3):174-80.
doi: 10.1038/nrneph.2013.280. Epub 2014 Jan 14.

Cardiovascular complications in atypical haemolytic uraemic syndrome

Affiliations
Review

Cardiovascular complications in atypical haemolytic uraemic syndrome

Marina Noris et al. Nat Rev Nephrol. 2014 Mar.

Abstract

Haemolytic uraemic syndrome (HUS) is characterized by nonimmune haemolytic anaemia, thrombocytopenia and renal impairment-most incidents in childhood are caused by shiga toxin-producing bacteria. Atypical HUS (aHUS) accounts for 10% of cases and has a poor prognosis. About 60% of patients with aHUS have dysregulation of the alternative complement pathway (complement-mediated aHUS). The kidney is the main target organ, but other organs might also be affected. Cardiac complications occur in 3-10% of patients with complement-mediated aHUS, as a consequence of microangiopathic injury in the coronary microvasculature, and can cause sudden death. Emerging evidence also suggests that either thrombosis or stenosis of the medium and large arteries might complicate disease course, and such disorders occur even after renal function is lost. In this Perspectives article we discuss the impact of cardiovascular involvement in complement-mediated aHUS, the role of acute and chronic complement hyperactivation in such events and the implications for treatment.

PubMed Disclaimer

References

    1. Nat Rev Immunol. 2009 Oct;9(10):729-40 - PubMed
    1. Am J Kidney Dis. 2013 Feb;61(2):289-99 - PubMed
    1. Blood. 2012 Jan 12;119(2):591-601 - PubMed
    1. Mol Immunol. 2009 Sep;46(14):2753-66 - PubMed
    1. Pediatr Nephrol. 2003 May;18(5):465-7 - PubMed

MeSH terms

LinkOut - more resources